These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9373324)

  • 61. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
    Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
    J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
    Pinter A; Honnen WJ; D'Agostino P; Gorny MK; Zolla-Pazner S; Kayman SC
    J Virol; 2005 Jun; 79(11):6909-17. PubMed ID: 15890930
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.
    Hioe CE; Wrin T; Seaman MS; Yu X; Wood B; Self S; Williams C; Gorny MK; Zolla-Pazner S
    PLoS One; 2010 Apr; 5(4):e10254. PubMed ID: 20421997
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity.
    Nishiyama Y; Planque S; Mitsuda Y; Nitti G; Taguchi H; Jin L; Symersky J; Boivin S; Sienczyk M; Salas M; Hanson CV; Paul S
    J Biol Chem; 2009 Oct; 284(44):30627-42. PubMed ID: 19726674
    [TBL] [Abstract][Full Text] [Related]  

  • 66. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.
    Mester B; Manor R; Mor A; Arshava B; Rosen O; Ding FX; Naider F; Anglister J
    Biochemistry; 2009 Aug; 48(33):7867-77. PubMed ID: 19552398
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.
    Vancott TC; Polonis VR; Loomis LD; Michael NL; Nara PL; Birx DL
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1379-91. PubMed ID: 8573396
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.
    Gorny MK; Xu JY; Karwowska S; Buchbinder A; Zolla-Pazner S
    J Immunol; 1993 Jan; 150(2):635-43. PubMed ID: 7678279
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Two PBMC-based neutralization assays depict low reactivity of both anti-V3 monoclonal antibodies and immune sera against HIV-1 primary isolates.
    Candotti D; Rosenheim M; Huraux JM; Agut H
    J Virol Methods; 1997 Feb; 64(1):81-93. PubMed ID: 9029533
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mutations of the HIV type 1 V3 loop under selection pressure with neutralizing monoclonal antibody NM-01.
    Yoshida K; Nakamura M; Ohno T
    AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1283-90. PubMed ID: 9339845
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice.
    Boudet F; Keller H; Kieny MP; Thèze J
    Mol Immunol; 1995 May; 32(7):449-57. PubMed ID: 7783749
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
    Zvi A; Feigelson DJ; Hayek Y; Anglister J
    Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop.
    Yoshiyama H; Mo H; Moore JP; Ho DD
    J Virol; 1994 Feb; 68(2):974-8. PubMed ID: 7507188
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs.
    Stanfield R; Cabezas E; Satterthwait A; Stura E; Profy A; Wilson I
    Structure; 1999 Feb; 7(2):131-42. PubMed ID: 10368281
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitidis.
    Wang J; Jarvis GA; Achtman M; Rosenqvist E; Michaelsen TE; Aase A; Griffiss JM
    Infect Immun; 2000 Apr; 68(4):1871-8. PubMed ID: 10722576
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.
    Gorny MK; Moore JP; Conley AJ; Karwowska S; Sodroski J; Williams C; Burda S; Boots LJ; Zolla-Pazner S
    J Virol; 1994 Dec; 68(12):8312-20. PubMed ID: 7525987
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120.
    Bagley J; Dillon PJ; Rosen C; Robinson J; Sodroski J; Marasco WA
    Mol Immunol; 1994 Oct; 31(15):1149-60. PubMed ID: 7935503
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.
    Zwick MB; Parren PW; Saphire EO; Church S; Wang M; Scott JK; Dawson PE; Wilson IA; Burton DR
    J Virol; 2003 May; 77(10):5863-76. PubMed ID: 12719580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.